Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL

THURSDAY, May 30, 2019 -- For high-risk and older patients with previously untreated chronic lymphocytic leukemia (CLL), the combination of ibrutinib and venetoclax is an active regimen, according to a study published in the May 30 issue of the New...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news